Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT00791882
Other study ID # SST
Secondary ID
Status Recruiting
Phase N/A
First received November 14, 2008
Last updated November 27, 2009
Start date August 2009
Est. completion date August 2011

Study information

Verified date November 2009
Source University of Sao Paulo
Contact Helio Elkis, MD PhD
Phone + 55 11 30697531
Email helkis@usp.br
Is FDA regulated No
Health authority Brazil: Ministry of HealthBrazil: National Committee of Ethics in Research
Study type Interventional

Clinical Trial Summary

Objective Primary:

To evaluate the efficacy of social skills training in reducing negative symptoms in patients with refractory schizophrenia, in comparison with control (befriending group).

Secondary:

To evaluate changes in social functioning.

To evaluate the effect of SST in other dimensions of psychopathology: positive symptoms, depression and general psychopathology.

To evaluate the impact of SST in cognition.

Hypothesis Social skills training is more effective than control group (Befriending) in reducing negative symptoms in patients with refractory schizophrenia.


Description:

In schizophrenia positive symptoms can be improved with an antipsychotic treatment. However there is a subgroup of patients who have a predominance of persistent negative symptoms that do not respond to antipsychotic treatment, such as blunted affect , emotional and social withdrawal, and there is evidence that such symptoms can improve with psychosocial interventions.

The objective of this study is to evaluate the efficacy of Social Skills Training on negative symptoms in patients with refractory schizophrenia by means of a randomized, single-blind controlled trial with the duration of a year, including, follow up.

This study will be conducted in two groups: one group will receive social skills training (N=46) and a control group (N=46) will attend the same number of sessions, but without intervention of the therapists (befriending).

Psychiatric, psychological and neuropsychological aspects will be evaluated at baseline, after 20 weeks and 6 months after the end of the intervention.

The scales that will be used for the psychiatric assessments are: PANSS (reduction of 20% in the negative subscale), CGI, CALGARY, SDS, and PSP, As well as the Social Skills Inventory IHS. The neuropsychological assessment will have groups of scales to measure: Attention, Memory, Executive Functions, Estimated Intellectual Efficiency and a ToM. For statistical , the repeated measure ANOVA will be used, as well as the effect size and number needed to treat.


Recruitment information / eligibility

Status Recruiting
Enrollment 92
Est. completion date August 2011
Est. primary completion date August 2011
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria:

- Diagnosis of schizophrenia canĀ“t not be over 10 years old.

- Age between 18 and 55 years old.

- A minimum of 16 in negative subscale of PANSS.

- A score 4 in at least 3 of the following symptoms:

- blunted affect

- social withdrawal

- rapport

- passive social withdrawal

- lack of spontaneity

- motor retardation

- active social avoidance

- Stable disease, in use of clozapine, without recent hospitalization.

Exclusion Criteria:

- Comorbid substance use.

- Axis I comorbidity.

- History of head trauma or neurological disease.

- Clinical problems which can affect central nervous system.

- Mental retardation.

- Patients treated with other antipsychotic than clozapine.

- Patients who underwent other psychosocial treatments.

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment


Related Conditions & MeSH terms

  • Schizophrenia
  • Schizophrenia and Disorders with Psychotic Features

Intervention

Behavioral:
Social Skills Training
A program developed during 20 weeks according to adapted BELLACK 's manual (1997),including sessions in group one hour per week.

Locations

Country Name City State
Brazil Instituto de Psiquiatria do HCFMUSP São Paulo

Sponsors (1)

Lead Sponsor Collaborator
University of Sao Paulo

Country where clinical trial is conducted

Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Primary Response: at least 20% decrease at PANSS - negative subscale after 20 weeks, in comparison with baseline, maintained at 26 weeks follow-up. 20 weeks treatment No
Secondary Improvement at PSP scores 20 weeks after treatment No
See also
  Status Clinical Trial Phase
Completed NCT01196858 - Duration of Untreated Psychosis (DUP) and Pathways to Care in Nordland N/A
Completed NCT00136760 - Contingent Incentives Plus Bupropion for Smoking in People With Schizophrenia Phase 2
Completed NCT03309475 - Effectiveness of a Mindfulness-based Group Training Addressing Social Cognition in First Episode Psychosis (AGES-Mind) N/A
Not yet recruiting NCT01968161 - Investigator Initiated Study - Asenapine Early Psychosis Phase 4
Completed NCT00135772 - Nicotine and Cotinine Levels in Smokers With Schizophrenia and Schizoaffective Disorder - 2 N/A
Completed NCT02308462 - Implementation and Evaluation of a Family-based Intervention Program for Children of Mentally Ill Parents N/A
Completed NCT03133143 - Video Games Among People With Schizophrenia N/A
Completed NCT00309452 - Specialized Treatment Early in Psychosis (STEP) N/A
Not yet recruiting NCT02240173 - Antipsychotic Effects of Sorghum Bicolor (JOBELYN) in the Treatment of Schizophrenia Phase 1/Phase 2
Completed NCT00218218 - Effects of Transdermal Nicotine on Smoking, Craving and Withdrawal in People With Schizophrenia Phase 2
Completed NCT02321943 - Anomalous Self-Experience in First Episode Psychosis - A Six-Year Follow-Up Study N/A
Completed NCT02928965 - The Benefit of Minocycline on Negative Symptoms in Schizophrenia: Extent and Mechanisms Phase 2
Completed NCT02307396 - Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients Phase 4
Terminated NCT00748566 - One-Year Trial Of Oral Ziprasidone In Patients With Metabolic Syndrome Phase 4
Completed NCT00363181 - Side Effects of Antipsychotic Medications
Completed NCT00137189 - Resource-oriented Music Therapy for Psychiatric Patients With Low Therapy Motivation N/A